Regulatory milestones

Actelion Ltd. (SIX:ATLN) was up CHF0.96 to CHF45.90 last week after EMA accepted for review an MAA for Opsumit macitentan to treat pulmonary arterial hypertension (PAH). The company submitted an NDA to FDA in October.